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SIONS: Patients starting a treatment with COXIBs +
GPAs are likely to have a previous history of GIDs sig-
niﬁcantly more severe and costly than patients who 
continue NSAIDs + GPAs. This constitutes a confound-
ing factor when assessing therapy effectiveness and safety,
in particular when evaluating co-prescription rates with
GPAs in patients treated with antinﬂammatories.
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ANALYSIS OF CONSUMPTION OF NON-
STEROID ANTIINFLAMMATORY DRUGS (GROUP
M01) AT NATIONAL LEVEL IN DDD/1000/DAY:
1999–2001
Borissov BN, Popova MJ, Kulaksazova RA
Bulgarian Drug Agency, Soﬁa, Bulgaria
OBJECTIVES: To focus on the Bulgarian market of M01
group for the period 1999–2001; the most consumptive
active principles (APs) within M01; to determine the
trend in M01 consumption and within. METHODS:
M01 consumption at national level has been calculated
by ATC/DDD methodology and expressed in
DDD/1000/day. Data have been collected from: a) the
import of wholesalers, b) the local industry sale reports
for the domestic market. Comparison has been made with
M01 consumption in Norway and Sweden (expressed 
in DDD/1000/day). RESULTS: M01 consumption at
national level has been calculated as follows: 1999—
14,216; 2000—13,764; and 2001—15,565. The most
consumptive APs within M01 were: Diclofenac (D)
1999—8,448; 2000—8,728; and 2001—9,753; Piroxi-
cam (P) 1999—3,380; 2000—2,892; and 2001—2,761;
Indometacin (Ind) 1999—1,457; 2000—1,061; and
2001—1,104; Ketoprofen (K) 1999—0,192; 2000—
0,439; and 2001—0,699; Tenoxicam (T) 1999—0,598;
2000—0,172; and 2001—0,699. Ibuprofen (Ib) con-
sumption was: 1999—0,169; 2000—0,030; and 2001—
0. The coxib Rofecoxib (R) consumption was registered
initially in 2001—0,054. CONCLUSIONS: M01 con-
sumption 1999–2001 did not show signiﬁcant variations.
The national demand for M01 is approximately 14
DDD/1000/day. M01 consumption in Norway and
Sweden was higher. D as the most consumptive AP at a
national level was about 67% of M01 consumption due
to 4 locally produced products. Dynamics within the
group was: D and K increased slightly; Ind showed rela-
tively steady-state position; P slightly decreased; the trend
in T consumption could not be deﬁned distinctly; Ib
decreased in consumption; Coxibs were with limited
place within M01. In comparison with Bulgaria, M01
consumption model in Norway and Sweden showed some
differences.
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OBJECTIVES: Osteoporosis, breast cancer and cardio-
vascular diseases are the main health problems among
postmenopausal women. We aimed to compare the cost-
effectiveness of raloxifene, alendronate or nasal calcitonin
in postmenopausal women, taking into account available
evidence for their preventive effect on a hip, vertebral,
wrist and ankle fractures, breast cancer, stroke and
myocardial infarction risk. METHODS: Markov model
was constructed to perform CEA and CUA over three
years from a health-care payers perspective, based on
Polish data on health-care resource utilisation and unit
cost. Treatment efﬁcacy and utility were derived from the
literature. Target population were patients aged 60–70,
without (group I) and with or without (group II) previ-
ous vertebral fracture. The outcomes measures were LYG
and QALYs gained, calculated on the basis of available
evidence for a preventive effect on an osteoporotic frac-
tures, breast cancer and cardiovascular events risk. The
cost-effectiveness threshold was calculated on basis of 1-
year haemodialysis treatment cost (60000 PLN, 1 USD =
4 PLN). The one-way and two-way sensitivity analysis
were performed. RESULTS: The highest effectiveness in
terms of LYG and QALYs was achieved with raloxifene
treatment, calcitonin was the least effective and the most
costly strategy. Incremental analysis suggests, that ralox-
ifene compared to alendronate was cost-effective: the
ICER was 15,975 PLN/LYG and 14,039 PLN/QALY
gained in group I, and 20,730 PLN/LYG and 17,915
PLN/QALY gained in group II. Sensitivity analyses
demonstrated robustness of the results in all cases calci-
tonin remained dominated strategy and ICER raloxifene
vs alendronian was below cost-effectiveness threshold.
CONCLUSIONS: Given the results of the analysis, in
osteoporotic postmenopausal women calcitonin is less
effective and more costly than alendronate and ralox-
ifene. Raloxifene can be considered as cost-effective when
compared with alendronate and within the Polish context
offers substantial beneﬁt at reasonable cost.
CARDIOVASULAR DISEASES/DISORDERS—
Economic Outcomes
PCV1
AN ECONOMIC EVALUATION OF
CLOPIDOGREL IN SECONDARY PREVENTION
OF ISCHEMIC EVENTS: HIGH RISK
POPULATIONS
Levy E1, Gabriel S2, Carita P2, Dinet J2
1Mediconomie, Paris, France; 2Sanoﬁ-Synthelabo, Bagneux,
France
478 Abstracts
OBJECTIVES: To determine the incremental cost per life
year saved (CLYS) for France, Germany and UK, of clopi-
dogrel versus aspirin in secondary prevention of ischemic
events (myocardial infarction, ischemic stroke, vascular
death) in three high-risk populations of atherothrombotic
patients (history of cardiac surgery, prior ischemic stroke
or myocardial infarction, hypercholesterolemia or dia-
betes) from the CAPRIE randomised clinical trial.
METHODS: A Markov model designed with several clin-
ical states calculated CLYS as the cost needed to achieve
an extra life year with clopidogrel compared with aspirin.
The model combined rates of clinical outcomes (fatal or
non-fatal) reported in CAPRIE, with survival data derived
from the Framingham database and costs of outcomes
assessed from external sources. Life expectancy was cor-
rected according to the level of risk of patients. The eco-
nomic analysis was performed with local unit costs from
the health care system perspective with a time horizon 
of two years. Both costs and beneﬁts were discounted
(according to local guidelines). CLYS obtained for high
risk populations were compared with CLYS calculated for
the overall CAPRIE population. RESULTS: For France,
when compared to CLYS obtained for overall population
(€15,907), CLYS for patients with history of prior cardiac
surgery was decreased by 90% (€1,570), CLYS for
patients with prior ischemic stroke or myocardial infarc-
tion by 55% (€7,202) and by 24% for CLYS for popu-
lation with hypercholesterolemia or diabetes (€12,018).
Similar decreases in ratios for these high-risk populations
were found in Germany and UK. CONCLUSION:
The economic analysis shows more favourable cost-
effectiveness results for high-risk populations compared
to overall CAPRIE population. All CLYS ﬁgures are
within acceptable ranges and compare favourably with
other therapeutic strategies for secondary prevention of
ischemic events.
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PHYSICIAN CHARACTERISTICS OF THE
NAVIGATOR TRIAL PREDICT AVERAGE LENGTH
OF STAY (ALOS) IN ACUTE CORONARY
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OBJECTIVES: The NAVIGATOR trial will evaluate the
impact of nateglinide and valsartan on the progression to
diabetes in subjects with impaired glucose tolerance at
high risk for a cardiovascular event. Investigators in this
trial include endocrinologists, cardiologists and general
internists. Although economic evaluations of clinical
trials typically adjust for country, little is known about
how physician-speciﬁc characteristics may affect ALOS.
Our objective was to determine which physician charac-
teristics would be independent predictors of ALOS for
myocardial infarction (MI). METHODS: We analyzed
responses from a survey of NAVIGATOR investigators to
determine factors associated with self-reported ALOS in
the treatment of MI. Candidate predictors in the multi-
ple regression model were physician age, sex, years since
graduation, medical specialty, practice environment, and
geographic region. This relationship was examined using
linear regression. RESULTS: 385 respondents with com-
plete data were included in the model. Physician age, 
sex, years since graduation, specialty of internal medicine,
practice setting (solo or group), and geographic region
met the criterion for inclusion in the multivariable model.
Male physicians reported an ALOS 3 days shorter than
female doctors (p = < .0001). Physicians in group prac-
tice were associated with a 1-day longer ALOS as com-
pared to hospital-afﬁliated physicians (p = < .0001). All
geographic regions except for Africa and Canada were 
signiﬁcantly associated with longer ALOS than the US
(Asia Paciﬁc 6 days, Eastern Europe 9, Europe 3.5, Latin
America 2) (p = < .0001 for all). CONCLUSIONS: For
NAVIGATOR investigators, physician sex, practice
setting and geographic region are predictors of ALOS. We
will adjust for physician characteristics in the economic
analysis of the NAVIGATOR trial. We conclude that mea-
suring physician characteristics should be incorporated
into multinational clinical trials.
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